Augsburg

• Efficacy and Safety of JNJ-77242113 in Participants with Moderately to Severely Active Ulcerative Colitis Ended
  2023-504673-20-00 4 2023-12-06 Ulcerative Colitis
• A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or … Ended
  2023-503689-21-00 9 2023-12-05 Multiple myeloma (MM)
• A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS Ended
  2023-503802-35-00 5 2023-11-29 Idiopathic or diabetic gastroparesis with moderate to severe nausea.
• A Study to Evaluate CC-486 in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Cancer Partic … Ended
  2023-503427-26-00 3 2023-11-10 Myeloid malignancies with moderate or severe hepatic impairment or nor
• A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended
  2022-500777-14-00 4 2023-11-06 Atopic Dermatitis
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended
  2022-500897-32-00 5 2023-11-02 Chronic pain due to diabetic polyneuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended
  2022-500898-13-00 5 2023-11-02 Chronic Pain due to traumatic or post-operative peripheral Neuropathy
• Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended
  2022-500899-66-00 5 2023-11-02 Chronic pain due to central Neuropathy of any Genesis
• Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended
  2022-502151-54-00 5 2023-11-02 Chronic back pain
• A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-S … Ended
  2023-505558-16-00 5 2023-10-24 Atopic Dermatitis
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe … Ended
  2022-501884-41-00 5 2023-09-29 Contrast enhancement in magnetic resonance imaging for assessment of c
• Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors Ended
  2022-502787-20-00 4 2023-09-28 Melanoma and squamous cell carcinoma of the head and neck
• A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The … Ended
  2024-512767-30-00 4 2023-09-28 Eosinophilic Esophagitis
• A Multi-national Phase IIIb Trial to Determine the Safety and Efficacy of STALORAL® Birch 300 IR in Children and Adolescents 5 to 17 Years o … Ended
  2023-509833-38-00 5 2023-09-20 Birch Pollen-induced Allergic Rhinoconjunctivitis
• HU-F-AIM - A prospective, interventional clinical study to evaluate hydroxyurea (HU) resistance in patients with polycythaemia vera who meet … Ended
  2022-502338-20-00 6 2023-07-28 Polycythemia vera
• ZN-c3 in Adult Participants With Metastatic Colorectal Cancer Ended
  2022-502267-37-00 9 2023-07-17 metastatic colorectal cancer
• A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Modera … Ended
  2022-502575-30-00 5 2023-05-23 Atopic Dermatitis
• A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous … Ended
  2024-516300-41-00 5 2023-03-07 Multiple Myeloma
• Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af … Ended
  2024-510590-14-00 5 2023-03-03 multiple myeloma
• Efficacy of [18F]florbetaben PET for diagnosis of cardiac AL amyloidosis Ended
  2022-500186-27-00 5 2023-01-11 ATTR Amyloidosis
• Clinical study to show if Naronapride tablets are safe and efficient for treatment of delayed stomach emptying and to find the optimal dose. Ended
  2023-510195-31-00 4 2023-01-03 Idiopathic or Diabetic Gastroparesis
• PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harbori … Ended
  2024-512018-16-00 4 2022-11-11 locally advanced intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fus
• A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch … Ended
  2024-516988-87-00 4 2022-11-09 Chronic Inducible Urticaria
• Efficacy and Safety of Neoadjuvant Olaparib Monotherapy and Olaparib Plus Durvalumab Combination in HER2-Negative BRCAm Breast Cancer Ended
  2023-503529-20-00 4 2022-10-17 BRCA Mutations and Early Stage HER2-Negative Breast Cancer

Showing 241–264 of 283 trials